Harnessing the Immune System to Break Tolerance

AIM aAPC Provides Direct T Cell Stimulation

  • Because AIM aAPC are not subject to suppression or regulation by Treg cells in the tumor microenvironment, they bypass the need for/role of host Dendritic cells
  • No genetic manipulation of T cells - unlike transgenic T cells, autologous naïve T cells have undergone central tolerance in the host, minimizing risk of on-target autoimmunity
  • Kinetics of T cell engagement mimics natural biology – access to internal cellular signaling mechanisms decreases risk of ACS syndrome
  • Naive T cell repertoire generates multiple clones of T central and T effector memory cells for effective and persistent anti-tumor effects

AIM aAPC Deploy Multiple Tumor Antigens in a Single Therapeutic

  • Enhances probability of engaging antigen(s) with highest cytotoxic activity
  • Minimizes chance of tumor escape
  • Ability to match antigen (epitope) selection with tumor expression and T cell response increases probability of robust and durable response

AIM aAPC - Potential for Clinical Benefit Independent of Tumor Type and Tumor Micro-environment

    • Designed to work independent of tumor micro-environment or somatic mutational burden
    • Pre-clinical effect in both solid and liquid tumors
    • Efficacy not influenced by availability or ‘health’ of host immune cells
    • Provide antigen-specific stimulation using allogeneic and/or autologous T cell sources

AIM aAPC - Benefits of Cellular Therapy Delivered with Pharmaceutical Precision
    • AIM aAPC can stimulate antigen-specific T cells either by direct in vivo administration as a pharmactical product, or, by ex vivo stimulation of T cells for delivery as an adoptive cellular therapy.
    • Simple design substitutions of antigen presentation on the AIM aAPC surface allow for production of aAPC treatment targeting a variety of cancers.
    • AIM aAPC can be precisely engineered, scaled and reproducibly manufactured within precise specifications